The Eigen Therapeutics team. Front row (L-R): Senior scientist Anukriti Dhar, associate scientist Molly Volkman, CSO Kathryn Vanderlaag. Back row (L-R): Lead engineer Erik Werner, CEO Transon Nguyen, CTO Kamran Ali
Priming therapy biotech emerges from stealth with seed funding — and on a hunt for partners
At Eigen Therapeutics, the goal is to make cancer treatment more effective. But not by making targeted drugs.
With $7 million in seed funding announced …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
